Fimmic closes investment round to digitalize cancer diagnostics
Fimmic, a Finnish Bio-IT startup, announces today that it has closed an investment round to accelerate the development of its next-generation cloud services for microscope image analysis. The funding, €1.5 M in total, was raised from new investors, including experienced IT business executives Mårten Mickos and Jukka Tapaninen, existing shareholders and Tekes, the Finnish funding agency for innovation.
Fimmic develops and sells novel cloud-based software services to the rapidly evolving field of digital microscopy. Fimmic’s WebMicroscope ® platform helps pathologists and researchers to store, share and analyze large, gigapixel-sizedimages of tissues and cell samples. WebMicroscope is used in several different applications, such as cancer research, drug development and medical education.
The new cloud service platform will expand Fimmic’s scope to diagnostics by employing machine vision and automated image analysis. It offers pathologists, microbiologists and researchers global access to fast, accurate and reproducible diagnostic support. Fimmic’s new digital services will support microscopy-based diagnostics in global health challenges, such as cancer and infectious diseases.
“We are pleased to have completed this financing round and to welcome worldclass experience to our investor team and board. It is exciting to ramp up our development project and execute our vision of automating microscopy-based diagnostics. Our novel, disruptive software tools will significantly improve the efficiency and accuracy of image-based diagnostics, and thus bring benefits to patients“, says Fimmic CEO Kaisa Helminen.
"Rapid and accurate diagnosis and analysis is a cornerstone of modern healthcare and medicine. Using innovative cloud technologies, Fimmic brings artificial intelligence tools for microscopy to the fingertips of pathologists, removing slow and manual workflow. As a result, experts can improve their decision-making workflow and patients get better and faster healthcare.", says Mårten Mickos, business leader and investor.
Fimmic Oy, a privately held company, was founded in 2013 based on the scientific and technological findings of Johan Lundin, MD, PhD, CSO at Fimmic and Mikael Lundin, MD, CTO at Fimmic. As a spin-off company from the Institute for Molecular Medicine Finland at the University of Helsinki, Fimmic has a strong academic background and collaboration network. Today, Fimmic’s WebMicroscope has thousands of users in Europe, North America and Middle East.